Side-by-side comparison of AI visibility scores, market position, and capabilities
Major media company with $41B revenue; HBO/Max streaming, Warner Bros. film, and CNN news after AT&T/Discovery merger competing with Netflix and Disney+ amid cable decline.
Warner Bros. Discovery is a major global media and entertainment company formed through the 2022 merger of WarnerMedia (spun out from AT&T) and Discovery, Inc. — combining Warner Bros. film studio, HBO/Max, CNN, TNT, TBS, Discovery Channel, HGTV, Food Network, Animal Planet, and the Max streaming platform under a single company. Listed on NASDAQ (NASDAQ: WBD) and led by CEO David Zaslav, Warner Bros. Discovery generates approximately $41 billion in annual revenue and competes across streaming, theatrical film, broadcast, and cable television.\n\nWarner Bros. Discovery's content portfolio spans some of the most valuable entertainment IP in media: DC Comics superheroes (Superman, Batman, The Flash), Harry Potter (Wizarding World), Looney Tunes, HBO prestige drama (House of the Dragon, Succession, The White Lotus), CNN news, March Madness (NCAA basketball), and Discovery's lifestyle programming (Chip and Joanna Gaines' Magnolia Network, 90 Day Fiancé). Max (formerly HBO Max) serves as the company's streaming platform with over 95 million global subscribers.\n\nIn 2025, Warner Bros. Discovery faces significant financial challenges from the debt load acquired through the merger and the secular decline of linear cable television advertising. The company has made significant cost cuts including laying off thousands of employees, canceling or not renewing content, and restructuring its streaming losses. The Max streaming service competes with Netflix, Disney+, and Apple TV+ for subscription streaming share. WBD's 2025 strategy focuses on improving Max's subscriber economics, maximizing theatrical film revenue from DC and Harry Potter franchises, managing the cable TV decline gracefully, and reducing the merger debt burden.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.